For years, GLP-1 weight loss meds have meant a weekly shot. That changed in December 2025, when the FDA approved a daily tablet version of semaglutide, the same medicine inside the Wegovy injection. It hit US pharmacies in early January 2026. If needles are the thing that's kept you on the fence, this is a genuinely new option worth understanding. Here's what it is, how well it works, and what it costs.

What's new

The new product is a high-dose oral form of semaglutide for chronic weight management. The FDA approved it on December 22, 2025, and Novo Nordisk had it in pharmacies and on telehealth platforms within about two weeks, with the starter dose priced at $149 a month for cash-paying patients. It comes in four tablet strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. You start low and step up month by month, the same slow-ramp idea as the injection, reaching the 25 mg maintenance dose from around day 91.

One thing worth saying plainly: this is not a new drug. It's the same semaglutide molecule that's been in Wegovy pens since 2021, reworked into a tablet with an absorption enhancer so it can survive your stomach. New format, familiar medicine.

Wait, isn't there already a semaglutide pill?

There is, and it's a common point of confusion. Rybelsus is an oral semaglutide tablet that's been around since 2019, but at lower doses (3, 7, and 14 mg) and approved for type 2 diabetes, not weight loss. The Wegovy pill is the same molecule taken up to a much higher 25 mg, and approved specifically for chronic weight management. Same drug family, different dose, different job. If someone offers you Rybelsus "for weight loss," that's off-label use of the diabetes product, not the new pill.

How well it works

In OASIS 4, the main weight loss trial, people taking the 25 mg pill who stayed on treatment lost an average of 16.6% of their body weight over 64 weeks, versus 2.7% on placebo. Counting everyone in the study, including people who stopped early, the average was about 13.6%. Roughly a third of those who stuck with it lost 20% or more.

How does that stack up? The weekly Wegovy injection produced about 15% in its main trial. Zepbound (tirzepatide) reached around 21% at its top dose and is still the most effective approved option. Foundayo (orforglipron), the other weight loss pill, approved in April 2026, came in lower at about 12.4% at its top dose over 72 weeks. So the Wegovy pill sits right alongside the Wegovy injection, ahead of Foundayo, behind Zepbound. One honest note: these are separate trials with different participants, so the comparison is indirect rather than head-to-head.

The morning routine (this is the real trade-off)

The big decision between pill and injection isn't really about effectiveness. It's about your mornings. Oral semaglutide is poorly absorbed, so the label is strict: take it once daily in the morning on an empty stomach, swallowed whole with no more than 4 ounces of plain water. No other liquids. Then wait at least 30 minutes before you eat, drink anything else, or take other oral medications.

That's a real commitment, every single day. Coffee first thing? Not anymore. Morning vitamins or thyroid medication? They now have to wait their turn. It's easy to slip up when the alarm doesn't go off and the kids need to be somewhere. The weekly injection has no food rules at all, but it does mean a shot once a week. Neither is better in the abstract. The pill suits people who hate needles or travel a lot and don't want anything in the refrigerator; the injection suits people who'd rather think about their medication once a week than build a careful morning ritual.

Worth knowing: Foundayo's whole pitch is that it has none of these restrictions. You can take it any time of day, with or without food. It lost less weight in its trial, but if the fasting routine is a dealbreaker for you, that's a conversation to have with your prescriber.

Side effects

Because it's the same class of medicine, the side effects look familiar. The common ones are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually mild to moderate and most noticeable while the dose is stepping up. The pill carries the same boxed warning as the injection about thyroid C-cell tumors seen in rodent studies, and the same list of things your prescriber checks before starting, which is exactly why it's prescription-only.

Cost and how to get it

Quick version, as of July 2026, because US pricing has moved twice this year already:

• Cash through NovoCare Pharmacy: $149 a month at the starter dose, rising to $299 a month at the 25 mg maintenance dose. GoodRx has agreed to match these cash prices at retail pharmacies. For context, Wegovy's list price is around $1,349 a month, which almost nobody actually pays.
• Commercial insurance: with coverage plus Novo's savings offer, some people pay as little as $25 a month. The savings card legally excludes anyone on Medicare, Medicaid, or TRICARE.
• Medicare: from July 1, 2026, the Medicare GLP-1 Bridge gives eligible Part D enrollees Wegovy, in all its forms including the pill, at a flat $50 monthly copay, running through the end of 2027.
• Telehealth: Hims & Hers, Ro, LifeMD, and WeightWatchers Clinic all prescribe and ship branded Wegovy, including the pill, at the same cash prices.

One warning. If you see a "compounded Wegovy pill" for $49 a month, walk away. Hims & Hers tried exactly that in February 2026 and pulled it within days under FDA pressure; compounded copies of semaglutide are no longer lawful now that the shortage is over, and anything still sold that way is a red flag. The branded cash prices have removed most of the reason to gamble anyway. Prices shift often, so verify the current numbers on novocare.com before you commit.

FAQs

Is there a Wegovy pill?

Yes. Once-daily oral semaglutide, up to a 25 mg maintenance dose. The FDA approved it on December 22, 2025, and it's been in US pharmacies since early January 2026.

Is the pill as effective as the injection?

Roughly, yes. About 16.6% weight loss over 64 weeks in people who stayed on it, similar to the injection's trial results. Zepbound remains more effective at its top dose. Suitability is always your prescriber's call.

Is the Wegovy pill the same as Rybelsus?

No. Both are oral semaglutide, but Rybelsus tops out at 14 mg and is approved for type 2 diabetes. The Wegovy pill goes up to 25 mg and is approved for weight management.

Does insurance cover it?

Increasingly, yes, though coverage varies by plan and many require prior authorization. With commercial coverage and the savings offer, some people pay as little as $25 a month; without coverage, NovoCare cash pricing runs $149 to $299 a month. Eligible Medicare Part D enrollees pay a $50 copay under the GLP-1 Bridge from July 2026.

Can I take it with my morning coffee?

No. Empty stomach, up to 4 ounces of plain water, then at least 30 minutes before anything else, coffee included. If that routine sounds unworkable, ask your prescriber about the injection or about Foundayo, which has no food or timing rules.